These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 10087035

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502).
    Nunoya K, Yokoi T, Kimura K, Inoue K, Kodama T, Funayama M, Nagashima K, Funae Y, Green C, Kinoshita M, Kamataki T.
    Pharmacogenetics; 1998 Jun; 8(3):239-49. PubMed ID: 9682269
    [Abstract] [Full Text] [Related]

  • 3. Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype.
    Nunoya K, Yokoi T, Takahashi Y, Kimura K, Kinoshita M, Kamataki T.
    J Biochem; 1999 Aug; 126(2):402-7. PubMed ID: 10423536
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP.
    Kitagawa K, Kunugita N, Katoh T, Yang M, Kawamoto T.
    Biochem Biophys Res Commun; 1999 Aug 19; 262(1):146-51. PubMed ID: 10448083
    [Abstract] [Full Text] [Related]

  • 6. Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method.
    Paschke T, Riefler M, Schuler-Metz A, Wolz L, Scherer G, McBride CM, Bepler G.
    Toxicology; 2001 Nov 30; 168(3):259-68. PubMed ID: 11684323
    [Abstract] [Full Text] [Related]

  • 7. (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes.
    Nunoya K, Yokoi Y, Kimura K, Kodama T, Funayama M, Inoue K, Nagashima K, Funae Y, Shimada N, Green C, Kamataki T.
    J Pharmacol Exp Ther; 1996 May 30; 277(2):768-74. PubMed ID: 8627557
    [Abstract] [Full Text] [Related]

  • 8. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F, Meyer UA.
    Pharmacogenetics; 1993 Jun 30; 3(3):123-30. PubMed ID: 8101460
    [Abstract] [Full Text] [Related]

  • 9. Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study.
    Evans WE, Relling MV.
    Mol Pharmacol; 1990 May 30; 37(5):639-42. PubMed ID: 1971090
    [Abstract] [Full Text] [Related]

  • 10. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.
    Skoda RC, Gonzalez FJ, Demierre A, Meyer UA.
    Proc Natl Acad Sci U S A; 1988 Jul 30; 85(14):5240-3. PubMed ID: 2899325
    [Abstract] [Full Text] [Related]

  • 11. Novel human CYP2A6 alleles confound gene deletion analysis.
    Nakajima M, Yoshida R, Fukami T, McLeod HL, Yokoi T.
    FEBS Lett; 2004 Jul 02; 569(1-3):75-81. PubMed ID: 15225612
    [Abstract] [Full Text] [Related]

  • 12. Characterization of a genotype previously designated as CYP2A6 D-type: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese.
    Ariyoshi N, Sekine H, Saito K, Kamataki T.
    Pharmacogenetics; 2002 Aug 02; 12(6):501-4. PubMed ID: 12172220
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method.
    Chen GF, Tang YM, Green B, Lin DX, Guengerich FP, Daly AK, Caporaso NE, Kadlubar FF.
    Pharmacogenetics; 1999 Jun 02; 9(3):327-32. PubMed ID: 10471064
    [Abstract] [Full Text] [Related]

  • 18. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism.
    Oscarson M, McLellan RA, Gullstén H, Agúndez JA, Benítez J, Rautio A, Raunio H, Pelkonen O, Ingelman-Sundberg M.
    FEBS Lett; 1999 Oct 29; 460(2):321-7. PubMed ID: 10544257
    [Abstract] [Full Text] [Related]

  • 19. Three haplotypes associated with CYP2A6 phenotypes in Caucasians.
    Haberl M, Anwald B, Klein K, Weil R, Fuss C, Gepdiremen A, Zanger UM, Meyer UA, Wojnowski L.
    Pharmacogenet Genomics; 2005 Sep 29; 15(9):609-24. PubMed ID: 16041240
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.